New medications that spur weight loss and address diabetes have been using the public—plus the pharmaceutical marketplace—by storm. The latest entrant, Zepbound, just lately joined Ozempic, Wegovy, Victoza and Other people in a very escalating class of medication identified as GLP-1 receptor agonists.Mounjaro, also identified by its Energetic i